Prostate Cancer

Probe for prostate cancer with Proteintech’s unparalleled range of products and take your IHC data to the next level

---

Introduction

Prostate cancer is one of the most common types of cancer in men; over a million new cases were recorded globally in 2020. Despite the high level of occurrence, prostate cancer is relatively curable thanks to screening methods that allow for it to be detected at an earlier stage of disease progression. However, since commonly used biomarkers can lack an exact specificity for cancer tissues, there can sometimes a tendency towards overdiagnosis. It is hence important to consider a combination of biomarkers when screening to achieve an accurate diagnosis. Proteintech offers a variety of antibodies and IHC kits against biomarkers for disease identification, tumor progression, and metastasis.

Featured Markers

PSA

Prostate-specific antigen (PSA), also know as KLK3, is a serine protease that is produced by prostate epithelial cells and secreted into the seminal fluid. High levels of PSA are usually not found in the blood. When this does occur, it is typically indicative of a potential problem within the prostate. This observation has led to PSA becoming the most widely used biomarker for detection of prostate cancer. While serum levels of PSA can be used to determine a prostate cancer diagnosis, evaluation of PSA expression in prostate tissue through IHC can be a way of monitoring disease progression. As prostate cancer cells differentiate and metastasize, they may downregulate PSA expression compared to tumors that have yet to become invasive.

Immunohistochemical analysis of paraffin-embedded human prostate cancer tissue slide using 10679-1-AP (KLK3/PSA antibody) at dilution of 1:500 (under 40x lens).

PTEN

PTEN is a tumor suppressor that is normally an antagonist of the PI3K signaling pathway. It specifically converts the lipid messenger, PIP3, back into its inactive form which in turn prevents excessive cell proliferation, adhesion, and migration. PTEN is commonly affected by loss of function mutations or other inactivating modifications in up to 20% of prostate cancers. These PTEN-deficient tumors tend to be more aggressive and resistant to therapy. IHC has become a preferred method of detection for PTEN loss as it can be used instances where loss of activity is a result of non-genomic alterations. Proteintech’s PTEN antibody is one of the top cited polyclonals against this target, trusted by over 120 researchers worldwide.

Immunohistochemical analysis of paraffin-embedded human prostate cancer tissue slide using 22034-1-AP (PTEN antibody) at dilution of 1:200 (under 10x lens).

ERG

ERG is a member of the ETS family of transcription factors that control of several cellular processes including cell proliferation, tissue remodeling, and vascular development. The ERG gene commonly fuses with other genes such as SLC45A3 or TMPRSS2 and these fusion products in turn become overexpressed in prostate cancer. Increased ERG expression helps to drive tumorigenesis of prostate tumors and can also promote metastasis when combined with dysregulation of PI3K pathway, which is also common in prostate cancer. ERG detection through IHC is said to be accurate enough to detect both fused and unfused forms of ERG.

Immunohistochemical analysis of paraffin-embedded human prostate cancer tissue slide using 14356-1-AP (ERG antibody) at dilution of 1:1200 (under 10x lens).

Antibodies for Prostate Cancer Research

Function	Marker	PTG Catalog
Angiogenesis	CD31	11265-1-AP
	COX2	12375-1-AP
	VEGFA	19003-1-AP
Cell Cycle, Growth, and Proliferation	AMACR	15918-1-AP
	ERBB3	10369-1-AP
	ERG	14356-1-AP
	Ki67	27309-1-AP
	KLK2	10812-1-AP
	Myc	67447-1-Ig
	P53	21891-1-AP
	P63	12143-1-AP
	PTEN	22034-1-AP
	uPA/Urokinase	17968-1-AP
Cancer Type Differentiation	ACPP	24410-1-AP
	NKX3-1	13069-1-AP
	PSA	10679-1-AP
	SLC45A3	60343-1-Ig
	TMPRSS2	14437-1-AP
Metastasis	CD147	11989-1-AP
	FOXA1	20411-1-AP
	PSMA	13163-1-AP

IHC Kits for Prostate Cancer Research

Function	Marker	PTG Catalog
Angiogenesis	CD31	KHC0022
	COX2	KHC0770
	VEGFA	KHC0735
Cell Cycle, Growth, and Proliferation	P53	KHC0079
	PTEN	KHC0280
Cancer Type Differentiation	PSA	KHC0065
Metastasis	FOXA1	KHC0139
	PSMA	KHC0066

References

Bonk, S., Kluth, M., Hube-Magg, C., Polonski, A., Soekeland, G., Makropidi-Fraune, G., Möller-Koop, C., Witt, M., Luebke, A. M., Hinsch, A., Burandt, E., Steurer, S., Clauditz, T. S., Schlomm, T., Perez, D. R., Graefen, M., Heinzer, H., Huland, H., Izbicki, J. R., . . . Simon, R. (2019). Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues. Oncotarget, 10(52), 5439–5453. https://doi.org/10.18632/oncotarget.27145

Chaux, A., Albadine, R., Toubaji, A., Hicks, J., Meeker, A. K., Platz, E. A., De Marzo, A. M., & Netto, G. J. (2011). Immunohistochemistry for ERG Expression as a Surrogate for TMPRSS2-ERG Fusion Detection in Prostatic Adenocarcinomas. The American Journal of Surgical Pathology, 35(7), 1014–1020. https://doi.org/10.1097/pas.0b013e31821e8761

Farha, M., & Salami, S. S. (2022). Biomarkers for prostate cancer detection and risk stratification. Therapeutic Advances in Urology, 14, 175628722211039. https://doi.org/10.1177/17562872221103988